Literature DB >> 6797109

Albinism. Recent advances.

B Jay, W Carroll.   

Abstract

There have recently been several fundamental advances in our understanding of albinism, both in animals and in man. These advances have been in the division of oculocutaneous albinism into tyrosinase-negative and tyrosinase-positive forms, the demonstration of a widespread disturbance in the structure of melanosomes in X-linked ocular albinism, the description of the condition now known as autosomal recessive ocular albinism, and a peculair anatomical abnormality of the visual pathways which appears to be present in all forms of oculocutaneous and ocular albinism. Evidence has been presented which confirms that the retinogeniculate anomaly in human albinos is similar to that in animals, and it has recently been suggested that there may be two major patterns of geniculocortical projected in man, as there are in the Siamese cat.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6797109

Source DB:  PubMed          Journal:  Trans Ophthalmol Soc U K        ISSN: 0078-5334


  4 in total

1.  Visual evoked cortical and subcortical potentials in human albinos.

Authors:  G F Harding; C Boylan; R A Clement
Journal:  Doc Ophthalmol       Date:  1986-01-31       Impact factor: 2.379

2.  Visual acuity development in tyrosinase negative oculocutaneous albinism.

Authors:  S G Jacobson; I Mohindra; R Held; T P Dryja; D M Albert
Journal:  Doc Ophthalmol       Date:  1984-02-29       Impact factor: 2.379

3.  The albino chick as a model for studying ocular developmental anomalies, including refractive errors, associated with albinism.

Authors:  Jodi Rymer; Vivian Choh; Shrikant Bharadwaj; Varuna Padmanabhan; Laura Modilevsky; Elizabeth Jovanovich; Brenda Yeh; Zhan Zhang; Huanxian Guan; W Payne; Christine F Wildsoet
Journal:  Exp Eye Res       Date:  2007-06-21       Impact factor: 3.467

4.  Dissociated vertical deviation: evidence of abnormal visual pathway projection.

Authors:  B A Fitzgerald; F A Billson
Journal:  Br J Ophthalmol       Date:  1984-11       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.